GlassScriptPhysician profile
Priyanka Bhat Krishnan
NPI 1497940712
$19,834.92
in general payments reported to CMS, 2019-2025
71 companies · $2,537 in 2025
The $2,537 reported for 2025 was more than what 80% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,776 · 2020: $2,143 · 2021: $3,323 · 2022: $2,789 · 2023: $3,007 · 2024: $3,261 · 2025: $2,537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,784 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,783.87 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,905.80 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Mannkind Corporation | $1,637.72 | 2019-2025 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,587.76 | 2019-2025 | Jardiance |
| Amgen INC. | $1,476.91 | 2019-2025 | Repatha, Evenity, Tepezza |
| Abbvie INC. | $1,340.44 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $923.17 | 2021-2025 | |
| Novo Nordisk INC | $892.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $712.92 | 2019-2024 | Farxiga, Airsupra |
| Dexcom, INC. | $710.75 | 2020-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Sanofi-Aventis U.S. LLC | $699.62 | 2019-2025 | |
| Abbott Laboratories | $617.89 | 2019-2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $534.29 | 2021-2025 | Nexletol |
| Corcept Therapeutics | $456.89 | 2020-2025 | Korlym |
| Insulet Corporation | $456.82 | 2019-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $362.15 | 2020-2025 | Recorlev, Gvoke Hypopen |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priyanka Krishnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.